Kiniksa Pharmaceuticals, Ltd. (KNSA)

Market Cap	1.26B
Revenue (ttm)	301.77M
Net Income (ttm)	8.65M
Shares Out	70.62M
EPS (ttm)	0.12
PE Ratio	149.00
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	283,298
Open	17.68
Previous Close	17.61
Day's Range	17.45 - 18.05
52-Week Range	10.65 - 22.09
Beta	0.30
Analysts	Strong Buy
Price Target	29.00 (+62.19%)
Earnings Date	Apr 23, 2024

About KNSA

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arter...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 24, 2018
• Employees: 297
• Stock Exchange: NASDAQ
• Ticker Symbol: KNSA

Financial Performance

In 2023, KNSA's revenue was $270.26 million, an increase of 22.74% compared to the previous year's $220.18 million. Earnings were $14.08 million, a decrease of -92.32%.

Analyst Forecast

According to 3 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price forecast is $29.0, which is an increase of 62.19% from the latest price.

Price Target

$29.0

(62.19% upside)

Analyst Consensus: Strong Buy